Samsung Bioepis, Takeda to Co-Develop Biologic Therapies
Takeda Pharmaceutical and Samsung Bioepis, an Incheon, South Korea-headquartered biopharmaceutical company, have agreed to jointly fund and co-develop new biologic therapies.
The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, for treating severe acute pancreatitis.
Samsung Bioepis is a joint venture between Samsung BioLogics, a contract biologics manufacturer based in Seoul, Korea, and Biogen. Samsung Bioepis is advancing a pipeline of biosimilar candidates that includes six candidates that cover the therapeutic areas of immunology, oncology, and diabetes.
Source: Samsung Bioepis